UVC Disinfection: Backed by Science
When considering investing in UVC disinfection technology for your hospital or facility, it is important to look to third-party, independent research that validates the technology’s effectiveness in a real-world setting.
There are more than 20 independent, third-parties studies on Tru-D and its technology, including the first-ever randomized clinical trial on UVC disinfection, which was funded by the Centers for Disease Control and Prevention.
In the two-year, $2M study, Tru-D was shown to reduce bioburden and epidemiologically-important pathogens by 94%. This reduction in bioburden led to a 35% reduction in colonization and infections in hospital settings with 93% compliance of standard disinfection protocols. Individual hospital results may vary.